Neuropeptide receptors in the GI tract (VIP, substance P, NPY, CGRP) represent therapeutic targets for IBD, IBS, and other intestinal diseases — the gut's neural peptide system as a drug target landscape.
Key findingNeuropeptide receptors in the GI tract (VIP, substance P, NPY, CGRP) represent therapeutic targets for IBD, IBS, and other intestinal diseases — the g
What the researchers found
Neuropeptide receptors in the GI tract (VIP, substance P, NPY, CGRP) represent therapeutic targets for IBD, IBS, and other intestinal diseases — the gut's neural peptide system as a drug target landscape.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Neuropeptide receptors in intestinal disease: physiology and therapeutic potential.
Current pharmaceutical design, 16(9), 1091-105
Citation
Snoek, Susanne A; Borensztajn, Keren S; van den Wijngaard, René M; de Jonge, Wouter J. (2010). Neuropeptide receptors in intestinal disease: physiology and therapeutic potential.. Current pharmaceutical design, 16(9), 1091-105.